Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 82

1.

Testosterone Breakthrough Rates during Androgen Deprivation Therapy for Castration Sensitive Prostate Cancer.

Saad F, Fleshner N, Pickles T, Niazi T, Lukka H, Pouliot F, Martins I, Klotz L.

J Urol. 2020 Feb 25:101097JU0000000000000809. doi: 10.1097/JU.0000000000000809. [Epub ahead of print]

PMID:
32096678
2.

Canadian Urological Association-Canadian Urologic Oncology Group guideline on metastatic castration-naive and castration-sensitive prostate cancer.

So AI, Chi KN, Danielson B, Fleshner NE, Kapoor A, Niazi T, Pouliot F, Rendon RA, Shayegan B, Sridhar S, Vigneault E, Saad F.

Can Urol Assoc J. 2020 Feb;14(2):17-23. doi: 10.5489/cuaj.6384. Epub 2019 Dec 5. No abstract available.

3.

GLUT1 expression in high-risk prostate cancer: correlation with 18F-FDG-PET/CT and clinical outcome.

Meziou S, Ringuette Goulet C, Hovington H, Lefebvre V, Lavallée É, Bergeron M, Brisson H, Champagne A, Neveu B, Lacombe D, Beauregard JM, Buteau FA, Riopel J, Pouliot F.

Prostate Cancer Prostatic Dis. 2020 Jan 13. doi: 10.1038/s41391-020-0202-x. [Epub ahead of print]

PMID:
31932660
4.

Extragonadal Steroids Contribute Significantly to Androgen Receptor Activity and Development of Castration Resistance in Recurrent Prostate Cancer after Primary Therapy.

Pouliot F, Rouleau M, Neveu B, Toren P, Morin F, Vélot L, Ding K, Caron P, Lacombe L, Lévesque É, Klotz L, Guillemette C.

J Urol. 2019 Dec 17:101097JU0000000000000699. doi: 10.1097/JU.0000000000000699. [Epub ahead of print]

PMID:
31845837
5.

Kidney Cancer Research Network of Canada (KCRNC) consensus statement on the role of renal mass biopsy in the management of kidney cancer.

Lavallée LT, McAlpine K, Kapoor A, Pouliot F, Mason R, Violette PD, Bansal RK, Richard PO, Karakiewicz PI, Bhindi B, Maloni R, Pautler S, Lattouf JB, Kassouf W, Tanguay S, So A, Rendon RA, Breau RH.

Can Urol Assoc J. 2019 Dec;13(12):377-383. doi: 10.5489/cuaj.6176. Epub 2019 Sep 17. No abstract available.

6.

Glucuronidation of Abiraterone and Its Pharmacologically Active Metabolites by UGT1A4, Influence of Polymorphic Variants and Their Potential as Inhibitors of Steroid Glucuronidation.

Vaillancourt J, Turcotte V, Caron P, Villeneuve L, Lacombe L, Pouliot F, Lévesque É, Guillemette C.

Drug Metab Dispos. 2020 Feb;48(2):75-84. doi: 10.1124/dmd.119.088229. Epub 2019 Nov 14.

PMID:
31727674
7.

2019 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC).

Saad F, Aprikian A, Finelli A, Fleshner NE, Gleave M, Kapoor A, Niazi T, North SA, Pouliot F, Rendon RA, Shayegan B, Sridhar SS, So A, Usmani N, Vigneault E, Chi KN.

Can Urol Assoc J. 2019 Oct;13(10):307-314. doi: 10.5489/cuaj.6136. No abstract available.

8.

Plasma extracellular vesicles as phenotypic biomarkers in prostate cancer patients.

Joncas FH, Lucien F, Rouleau M, Morin F, Leong HS, Pouliot F, Fradet Y, Gilbert C, Toren P.

Prostate. 2019 Nov;79(15):1767-1776. doi: 10.1002/pros.23901. Epub 2019 Sep 2.

PMID:
31475741
9.

Neutrophil-to-lymphocyte Ratio as a Predictive Marker of Response to Abiraterone Acetate: A Retrospective Analysis of the COU302 Study.

Loubersac T, Nguile-Makao M, Pouliot F, Fradet V, Toren P.

Eur Urol Oncol. 2019 Jan 30. pii: S2588-9311(19)30010-0. doi: 10.1016/j.euo.2019.01.009. [Epub ahead of print]

PMID:
31411963
10.

Application of Hereditary Renal Cell Carcinoma Risk Criteria to a Large Prospective Database.

Kushnir I, Kirk L, Mallick R, Kim RH, Graham GE, Breau RH, Lattouf JB, Violette PD, Pautler SE, Care M, Kapoor A, Jewett MAS, Wood L, Tanguay S, Heng DYC, Basappa NS, So A, Pouliot F, Reaume NM.

Clin Oncol (R Coll Radiol). 2020 Jan;32(1):e10-e15. doi: 10.1016/j.clon.2019.07.010. Epub 2019 Aug 1.

PMID:
31378448
11.

Renal cell carcinoma in the Canadian Indigenous population.

Wong ECL, Breau RH, Mallick R, Wood L, Pouliot F, Basappa NS, Tanguay S, Soulières D, So A, Heng D, Lavallée LT, Drachenberg D, Kapoor A.

Curr Oncol. 2019 Jun;26(3):e367-e371. doi: 10.3747/co.26.4707. Epub 2019 Jun 1.

12.

Diabetes and kidney cancer survival in patients undergoing nephrectomy: A Canadian multi-center, propensity score analysis.

Nayan M, Jalali S, Kapoor A, Finelli A, So A, Rendon R, Breau RH, Lavallee LT, Tanguay S, Heng D, Kawakami J, Basappa NS, Bjarnason G, Pouliot F, Hamilton RJ.

Urol Oncol. 2019 Sep;37(9):576.e11-576.e16. doi: 10.1016/j.urolonc.2019.06.006. Epub 2019 Jul 5.

PMID:
31285115
13.

Morphologic subtyping as a prognostic predictor for survival in papillary renal cell carcinoma: Type 1 vs. type 2.

Wong ECL, Di Lena R, Breau RH, Pouliot F, Finelli A, Lavallée LT, So A, Tanguay S, Fairey A, Rendon R, Richard PO, Lattouf JB, Kawakami J, Mallick R, Kapoor A.

Urol Oncol. 2019 Oct;37(10):721-726. doi: 10.1016/j.urolonc.2019.05.009. Epub 2019 Jun 5.

14.

The Contribution of Multiparametric Pelvic and Whole-Body MRI to Interpretation of 18F-Fluoromethylcholine or 68Ga-HBED-CC PSMA-11 PET/CT in Patients with Biochemical Failure After Radical Prostatectomy.

Metser U, Chua S, Ho B, Punwani S, Johnston E, Pouliot F, Tau N, Hawsawy A, Anconina R, Bauman G, Hicks RJ, Weickhardt A, Davis ID, Pond G, Scott AM, Tunariu N, Sidhu H, Emmett L.

J Nucl Med. 2019 Sep;60(9):1253-1258. doi: 10.2967/jnumed.118.225185. Epub 2019 Mar 22.

PMID:
30902875
15.

Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.

Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, Pouliot F, Alekseev B, Soulières D, Melichar B, Vynnychenko I, Kryzhanivska A, Bondarenko I, Azevedo SJ, Borchiellini D, Szczylik C, Markus M, McDermott RS, Bedke J, Tartas S, Chang YH, Tamada S, Shou Q, Perini RF, Chen M, Atkins MB, Powles T; KEYNOTE-426 Investigators.

N Engl J Med. 2019 Mar 21;380(12):1116-1127. doi: 10.1056/NEJMoa1816714. Epub 2019 Feb 16.

PMID:
30779529
16.

Cancer-associated fibroblasts induce epithelial-mesenchymal transition of bladder cancer cells through paracrine IL-6 signalling.

Goulet CR, Champagne A, Bernard G, Vandal D, Chabaud S, Pouliot F, Bolduc S.

BMC Cancer. 2019 Feb 11;19(1):137. doi: 10.1186/s12885-019-5353-6.

17.

Discordance between testosterone measurement methods in castrated prostate cancer patients.

Rouleau M, Lemire F, Déry M, Thériault B, Dubois G, Fradet Y, Toren P, Guillemette C, Lacombe L, Klotz L, Saad F, Guérette D, Pouliot F.

Endocr Connect. 2019 Feb;8(2):132-140. doi: 10.1530/EC-18-0476.

18.

Development of a Transcriptional Amplification System Based on the PEG3 Promoter to Target Androgen Receptor-Positive and -Negative Prostate Cancer Cells.

Jain P, Clermont PL, Desmeules F, Zoubeidi A, Neveu B, Pouliot F.

Int J Mol Sci. 2019 Jan 8;20(1). pii: E216. doi: 10.3390/ijms20010216.

19.

Renal hypothermia during partial nephrectomy for patients with renal tumours: a randomised controlled clinical trial protocol.

Breau RH, Cagiannos I, Knoll G, Morash C, Cnossen S, Lavallée LT, Mallick R, Finelli A, Jewett M, Leibovich BC, Cook J, LeBel L, Kapoor A, Pouliot F, Izawa J, Rendon R, Fergusson DA.

BMJ Open. 2019 Jan 3;9(1):e025662. doi: 10.1136/bmjopen-2018-025662.

20.

Prospective, Multisite, International Comparison of 18F-Fluoromethylcholine PET/CT, Multiparametric MRI, and 68Ga-HBED-CC PSMA-11 PET/CT in Men with High-Risk Features and Biochemical Failure After Radical Prostatectomy: Clinical Performance and Patient Outcomes.

Emmett L, Metser U, Bauman G, Hicks RJ, Weickhardt A, Davis ID, Punwani S, Pond G, Chua S, Ho B, Johnston E, Pouliot F, Scott AM.

J Nucl Med. 2019 Jun;60(6):794-800. doi: 10.2967/jnumed.118.220103. Epub 2018 Nov 15.

21.

Symptom assessment to guide treatment selection and determine progression in metastatic castration-resistant prostate cancer: Expert opinion and review of the evidence.

Saad F, Pouliot F, Danielson B, Catton C, Kapoor A.

Can Urol Assoc J. 2018 Sep;12(9):E415-E420. doi: 10.5489/cuaj.5154. Epub 2018 May 14. Review.

22.

Canadian Urological Association guideline for followup of patients after treatment of non-metastatic renal cell carcinoma.

Kassouf W, Monteiro LL, Drachenberg DE, Fairey AS, Finelli A, Kapoor A, Lattouf JB, Leveridge MJ, Power NE, Pouliot F, Rendon RA, Sabbagh R, So AI, Tanguay S, Breau RH.

Can Urol Assoc J. 2018 Aug;12(8):231-238. doi: 10.5489/cuaj.5462. Epub 2018 May 31. No abstract available.

23.

Serum Sex Steroids as Prognostic Biomarkers in Patients Receiving Androgen Deprivation Therapy for Recurrent Prostate Cancer: A Post Hoc Analysis of the PR.7 Trial.

Toren P, Hoffman A, Ding K, Joncas FH, Turcotte V, Caron P, Pouliot F, Fradet Y, Lévesque É, Guillemette C, Klotz L.

Clin Cancer Res. 2018 Nov 1;24(21):5305-5312. doi: 10.1158/1078-0432.CCR-18-1187. Epub 2018 Jul 18.

24.

Modeling human bladder cancer.

Ringuette-Goulet C, Bolduc S, Pouliot F.

World J Urol. 2018 Nov;36(11):1759-1766. doi: 10.1007/s00345-018-2369-5. Epub 2018 Jun 14. Review.

PMID:
29948049
25.

Prostate-specific membrane antigen for prostate cancer theranostics: from imaging to targeted therapy.

Arsenault F, Beauregard JM, Pouliot F.

Curr Opin Support Palliat Care. 2018 Sep;12(3):359-365. doi: 10.1097/SPC.0000000000000357. Review.

PMID:
29939893
26.

Kidney Cancer Research Network of Canada consensus statement on the role of adjuvant therapy after nephrectomy for high-risk, non-metastatic renal cell carcinoma: A comprehensive analysis of the literature and meta-analysis of randomized controlled trials.

Karakiewicz PI, Zaffuto E, Kapoor A, Basappa NS, Bjarnason GA, Blais N, Breau RH, Canil C, Drachenberg D, Hotte SJ, Jeldres C, Jewett MAS, Kassouf W, Kollmannsberger C, Lavallée LT, Maloni R, Patenaude F, Pouliot F, Reaume MN, Sabbagh R, Shayegan B, So A, Soulières D, Tanguay S, Wood L, Bandini M.

Can Urol Assoc J. 2018 Jun;12(6):173-180. doi: 10.5489/cuaj.5187.

27.

Is Routine Renal Tumor Biopsy Associated with Lower Rates of Benign Histology following Nephrectomy for Small Renal Masses?

Richard PO, Lavallée LT, Pouliot F, Komisarenko M, Martin L, Lattouf JB, Finelli A.

J Urol. 2018 Oct;200(4):731-736. doi: 10.1016/j.juro.2018.04.015. Epub 2018 Apr 11.

PMID:
29653161
28.

Exosomes Induce Fibroblast Differentiation into Cancer-Associated Fibroblasts through TGFβ Signaling.

Ringuette Goulet C, Bernard G, Tremblay S, Chabaud S, Bolduc S, Pouliot F.

Mol Cancer Res. 2018 Jul;16(7):1196-1204. doi: 10.1158/1541-7786.MCR-17-0784. Epub 2018 Apr 10.

29.

Increased Prostate Cancer Glucose Metabolism Detected by 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Localised Gleason 8-10 Prostate Cancers Identifies Very High-risk Patients for Early Recurrence and Resistance to Castration.

Lavallée E, Bergeron M, Buteau FA, Blouin AC, Duchesnay N, Dujardin T, Tiguert R, Lacombe L, Fradet V, Makao-Nguile M, Fradet Y, Beauregard JM, Pouliot F.

Eur Urol Focus. 2019 Nov;5(6):998-1006. doi: 10.1016/j.euf.2018.03.008. Epub 2018 Mar 30.

PMID:
29609897
30.

A LATS biosensor screen identifies VEGFR as a regulator of the Hippo pathway in angiogenesis.

Azad T, Janse van Rensburg HJ, Lightbody ED, Neveu B, Champagne A, Ghaffari A, Kay VR, Hao Y, Shen H, Yeung B, Croy BA, Guan KL, Pouliot F, Zhang J, Nicol CJB, Yang X.

Nat Commun. 2018 Mar 13;9(1):1061. doi: 10.1038/s41467-018-03278-w.

31.

Follow-up imaging after nephrectomy for cancer in Canada: urologists' compliance with guidelines. An observational study.

Dragomir A, Aprikian A, Kapoor A, Finelli A, Pouliot F, Rendon R, Black PC, Moore R, Breau RH, Kawakami J, Drachenberg D, Lattouf JB, Tanguay S.

CMAJ Open. 2017 Dec 11;5(4):E834-E841. doi: 10.9778/cmajo.20170005.

32.

Prognostic value of urinary prostate cancer antigen 3 (PCA3) during active surveillance of patients with low-risk prostate cancer receiving 5α-reductase inhibitors.

Fradet V, Toren P, Nguile-Makao M, Lodde M, Lévesque J, Léger C, Caron A, Bergeron A, Ben-Zvi T, Lacombe L, Pouliot F, Tiguert R, Dujardin T, Fradet Y.

BJU Int. 2018 Mar;121(3):399-404. doi: 10.1111/bju.14041. Epub 2017 Oct 25.

33.

Tissue-engineered human 3D model of bladder cancer for invasion study and drug discovery.

Ringuette Goulet C, Bernard G, Chabaud S, Couture A, Langlois A, Neveu B, Pouliot F, Bolduc S.

Biomaterials. 2017 Nov;145:233-241. doi: 10.1016/j.biomaterials.2017.08.041. Epub 2017 Aug 29.

PMID:
28888113
34.

Benchmarking quality for renal cancer surgery: Canadian Kidney Cancer information system (CKCis) perspective.

Lawson KA, Saarela O, Liu Z, Lavallée LT, Breau RH, Wood L, Jewett MAS, Kapoor A, Tanguay S, Moore RB, Rendon R, Pouliot F, Black PC, Kawakami J, Drachenberg D, Finelli A.

Can Urol Assoc J. 2017 Aug;11(8):232-237. doi: 10.5489/cuaj.4397.

35.

Development and Implementation of a Continuing Medical Education Program in Canada: Knowledge Translation for Renal Cell Carcinoma (KT4RCC).

Lavallée LT, Fitzpatrick R, Wood LA, Basiuk J, Knee C, Cnossen S, Mallick R, Witiuk K, Vanhuyse M, Tanguay S, Finelli A, Jewett MAS, Basappa N, Lattouf JB, Gotto GT, Al-Asaaed S, Bjarnason GA, Moore R, North S, Canil C, Pouliot F, Soulières D, Castonguay V, Kassouf W, Cagiannos I, Morash C, Breau RH.

J Cancer Educ. 2019 Feb;34(1):14-18. doi: 10.1007/s13187-017-1259-7.

PMID:
28779441
36.

Metabolic Imaging of Prostate Cancer Reveals Intrapatient Intermetastasis Response Heterogeneity to Systemic Therapy.

Morin F, Beauregard JM, Bergeron M, Nguile Makao M, Lacombe L, Fradet V, Fradet Y, Pouliot F.

Eur Urol Focus. 2017 Dec;3(6):639-642. doi: 10.1016/j.euf.2017.02.007. Epub 2017 Feb 23.

37.

Testosterone monitoring for men with advanced prostate cancer: Review of current practices and a survey of Canadian physicians.

Shayegan B, Pouliot F, So A, Fernandes J, Macri J.

Can Urol Assoc J. 2017 Jun;11(6):204-209. doi: 10.5489/cuaj.4539. Review.

38.

New research in kidney cancer, ASCO-GU 2017.

Basappa N, Pouliot F.

Can Urol Assoc J. 2017 Jun;11(6Suppl2):S163-S165. doi: 10.5489/cuaj.4607. Review. No abstract available.

39.

Supplementary data: Maximal testosterone suppression in the management of recurrent and metastatic prostate cancer.

Klotz L, Breau RH, Collins LL, Gleave ME, Pickles T, Pouliot F, Saad F.

Can Urol Assoc J. 2017 Jan-Feb;11(1-2):E62-E63. doi: 10.5489/cuaj.4494. Epub 2017 Feb 20. Review. No abstract available.

40.

Maximal testosterone suppression in the management of recurrent and metastatic prostate cancer.

Klotz L, Breau RH, Collins LL, Gleave ME, Pickles T, Pouliot F, Saad F.

Can Urol Assoc J. 2017 Jan-Feb;11(1-2):16-23. doi: 10.5489/cuaj.4303. Review.

41.

A Multicentered, Propensity Matched Analysis Comparing Laparoscopic and Open Surgery for pT3a Renal Cell Carcinoma.

Patel P, Nayak JG, Liu Z, Saarela O, Jewett M, Rendon R, Kapoor A, Black P, Tanguay S, Kawakami J, Moore R, Breau RH, Morash C, Pouliot F, Drachenberg DE.

J Endourol. 2017 Jul;31(7):645-650. doi: 10.1089/end.2016.0787.

PMID:
28381117
42.

CUA guideline on the management of cystic renal lesions.

Richard PO, Violette PD, Jewett MA, Pouliot F, Leveridge M, So A, Whelan TF, Rendon R, Finelli A.

Can Urol Assoc J. 2017 Mar-Apr;11(3-4):E66-E73. doi: 10.5489/cuaj.4484. Epub 2017 Mar 16. No abstract available.

43.

Investigation of the In Vitro and In Vivo efficiency of RM-532-105, a 17β-hydroxysteroid dehydrogenase type 3 inhibitor, in LAPC-4 prostate cancer cell and tumor models.

Kenmogne LC, Roy J, Maltais R, Rouleau M, Neveu B, Pouliot F, Poirier D.

PLoS One. 2017 Feb 9;12(2):e0171871. doi: 10.1371/journal.pone.0171871. eCollection 2017.

44.

Corrigendum: Bioluminescence Microscopy as a Method to Measure Single Cell Androgen Receptor Activity Heterogeneous Responses to Antiandrogens.

Jain P, Neveu B, Velot L, Wu L, Fradet Y, Pouliot F.

Sci Rep. 2016 Nov 21;6:37381. doi: 10.1038/srep37381. No abstract available.

45.

Bioluminescence Microscopy as a Method to Measure Single Cell Androgen Receptor Activity Heterogeneous Responses to Antiandrogens.

Jain P, Neveu B, Velot L, Wu L, Fradet Y, Pouliot F.

Sci Rep. 2016 Sep 28;6:33968. doi: 10.1038/srep33968. Erratum in: Sci Rep. 2016 Nov 21;6:37381.

46.

Safety, reliability and accuracy of small renal tumour biopsies: results from a multi-institution registry.

Richard PO, Jewett MA, Tanguay S, Saarela O, Liu ZA, Pouliot F, Kapoor A, Rendon R, Finelli A.

BJU Int. 2017 Apr;119(4):543-549. doi: 10.1111/bju.13630. Epub 2016 Sep 7.

47.

Renal cell carcinoma with thrombus extending to the hepatic veins or right atrium: operative strategies based on 41 consecutive patients.

Gagné-Loranger M, Lacombe L, Pouliot F, Fradet V, Dagenais F.

Eur J Cardiothorac Surg. 2016 Aug;50(2):317-21. doi: 10.1093/ejcts/ezw023. Epub 2016 Mar 25.

PMID:
27016196
48.

Phase II Drug-Metabolizing Polymorphisms and Smoking Predict Recurrence of Non-Muscle-Invasive Bladder Cancer: A Gene-Smoking Interaction.

Lacombe L, Fradet V, Lévesque É, Pouliot F, Larue H, Bergeron A, Hovington H, Caron A, Nguile-Makao M, Harvey M, Fradet Y, Guillemette C.

Cancer Prev Res (Phila). 2016 Feb;9(2):189-95. doi: 10.1158/1940-6207.CAPR-15-0069. Epub 2015 Dec 8.

49.

A PCA3 gene-based transcriptional amplification system targeting primary prostate cancer.

Neveu B, Jain P, Têtu B, Wu L, Fradet Y, Pouliot F.

Oncotarget. 2016 Jan 12;7(2):1300-10. doi: 10.18632/oncotarget.6360.

50.

FDG-PET/CT for pre-operative staging and prognostic stratification of patients with high-grade prostate cancer at biopsy.

Beauregard JM, Blouin AC, Fradet V, Caron A, Fradet Y, Lemay C, Lacombe L, Dujardin T, Tiguert R, Rimac G, Bouchard F, Pouliot F.

Cancer Imaging. 2015 Mar 3;15:2. doi: 10.1186/s40644-015-0038-0.

Supplemental Content

Loading ...
Support Center